COMP <GO>
XFOR vs AGEN // GROSS PROFIT MARGIN
X4 Pharmaceuticals Inc. (NASDAQ) VS. Agenus Inc. (NASDAQ) • 15-METRIC TALLY: XFOR 3
— AGEN 3
▲ GROSS PROFIT MARGIN LEADER: AGEN
LAST: $3.36 (+0.30%) • MKT CAP: $333.1M
gross-margins
83.60%
LAST: $7.09 (-0.56%) • MKT CAP: $320.2M
gross-margins
96.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XFOR VS. AGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XFOR | AGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 83.60% | 96.00% | -12.40 | AGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -24.11% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | -17.70% | -42.30 | AGEN | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -2.70% | -57.30 | AGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 10.40% | +169.60 | XFOR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 46.7 | +13.61 | XFOR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $333.1M | $320.2M | $12.9M | XFOR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XFOR REV | AGEN REV | XFOR GROSS % | AGEN GROSS % | XFOR FCF | AGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $35.1M | $114.2M | 83.6% | 98.0% | -$85.6M | -$77.2M |
| FY 2024 | $2.6M | $103.5M | 68.8% | 98.0% | -$131.2M | -$158.9M |
| FY 2023 | $0 | $156.3M | — | — | -$96.5M | -$224.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XFOR // BETA —
AGEN // BETA —